LHC Group (LHCG) Receives “Buy” Rating from Oppenheimer
Oppenheimer reiterated their buy rating on shares of LHC Group (NASDAQ:LHCG) in a research report sent to investors on Thursday morning. Oppenheimer currently has a $85.00 price objective on the health services provider’s stock.
Other equities research analysts also recently issued reports about the company. Royal Bank Of Canada restated a buy rating and set a $70.00 price objective on shares of LHC Group in a report on Wednesday, September 6th. Bank of America initiated coverage on LHC Group in a report on Monday, August 21st. They set a buy rating and a $76.00 price objective on the stock. BidaskClub upgraded LHC Group from a hold rating to a buy rating in a report on Friday, August 18th. Zacks Investment Research upgraded LHC Group from a hold rating to a buy rating and set a $79.00 price objective on the stock in a report on Wednesday, November 8th. Finally, Craig Hallum restated a buy rating and set a $80.00 price objective (up from $67.00) on shares of LHC Group in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. LHC Group presently has a consensus rating of Buy and a consensus price target of $77.10.
Shares of LHC Group (NASDAQ:LHCG) opened at $62.09 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.24. LHC Group has a twelve month low of $41.66 and a twelve month high of $76.14. The stock has a market capitalization of $1,134.94, a P/E ratio of 26.65, a price-to-earnings-growth ratio of 1.84 and a beta of 0.69.
LHC Group (NASDAQ:LHCG) last posted its quarterly earnings data on Monday, November 6th. The health services provider reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. LHC Group had a return on equity of 9.52% and a net margin of 4.09%. The company had revenue of $272.90 million for the quarter, compared to the consensus estimate of $265.35 million. During the same period in the previous year, the business earned $0.54 EPS. LHC Group’s revenue for the quarter was up 18.2% compared to the same quarter last year. equities analysts anticipate that LHC Group will post 2.4 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of LHCG. BlackRock Inc. grew its position in shares of LHC Group by 18.1% in the 2nd quarter. BlackRock Inc. now owns 2,325,510 shares of the health services provider’s stock worth $157,879,000 after acquiring an additional 356,014 shares in the last quarter. Royal Bank of Canada boosted its position in LHC Group by 50,943.5% during the 2nd quarter. Royal Bank of Canada now owns 165,381 shares of the health services provider’s stock valued at $11,229,000 after purchasing an additional 165,057 shares during the period. Castleark Management LLC acquired a new position in LHC Group during the 2nd quarter valued at approximately $7,661,000. AJO LP acquired a new position in LHC Group during the 2nd quarter valued at approximately $6,300,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in LHC Group during the 3rd quarter valued at approximately $5,197,000. Institutional investors own 85.51% of the company’s stock.
LHC Group Company Profile
LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.
Receive News & Ratings for LHC Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.